Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2025; 17(5): 104522
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104522
Published online May 15, 2025. doi: 10.4251/wjgo.v17.i5.104522
Simvastatin inhibits proliferation and migration, promotes oxidative stress and ferroptosis in colon cancer
Ying Liu, Ting Lu, Lei He, Meng Li, Qiang Leng, Department of Colon and Rectal Surgery, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China
Hao Ge, Hao-Ran Zhao, Department of Traditional Chinese Medicine Surgery, First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210038, Jiangsu Province, China
Zhi-Min Fan, Department of Anorectal Medicine, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China
Co-first authors: Ying Liu and Hao Ge.
Author contributions: Leng Q, Liu Y and Ge H conceived and designed the study; Liu Y, Ge H, Lu T and Zhao HR performed the literature search and data extraction; He L, Li M and Fan ZM analyzed and interpreted the data and processed them statistically; Liu Y, Ge H and Zhao HR drafted the manuscript; Leng Q and Fan ZM confirm the authenticity of all the raw data and revise the manuscript; All authors read and approved the final manuscript.
Supported by the Jiangsu Province Key Research and Development Plan (Social Development) Project, No. BE2021611.
Institutional review board statement: This study does not involve animal experimentation or human subjects, and therefore does not require approval from the Institutional Animal Care and Use Committee or the Institutional Review Board. All the experiments reported in this manuscript were conducted in accordance with standard laboratory procedures, and no ethical review was required.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qiang Leng, MM, Doctor, Department of Colon and Rectal Surgery, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, No. 157 Daming Road, Qinhuai District, Nanjing 210022, Jiangsu Province, China.
Received: December 27, 2024
Revised: February 27, 2025
Accepted: April 21, 2025
Published online: May 15, 2025
Processing time: 143 Days and 1 Hours
Revised: February 27, 2025
Accepted: April 21, 2025
Published online: May 15, 2025
Processing time: 143 Days and 1 Hours
Core Tip
Core Tip: Simvastatin significantly reduces the proliferation and migration of HCT-116 and SW620 colon cancer cell lines in a dose-dependent manner, while promoting apoptosis. Treatment with simvastatin enhances oxidative stress markers (reactive oxygen species, malondialdehyde, ferrous ion) and decreases glutathione levels, indicating its potential to induce ferroptosis in colon cancer cells through the modulation of the cyclic guanosine monophosphate-protein kinase G signaling pathway. SERPINE1 was identified as a core target of simvastatin, with its downregulation linked to increased GUCY1B1 and PRKG1 levels, suggesting a crucial role in the drug’s mechanism of action.